# Why past GLP-1 users stop, and what brings them back: side effects (35.3%) and cost (31.2%) lead, and the fix must match the reason, with 94.3% of cost quitters wanting coverage under $50 and 60.0% of side-effect quitters a lower dose

*Why did past GLP-1 users stop, and what would bring them back?*

In October 2026, US past GLP-1 users most often said they stopped because of side effects (35.3%) or cost and lost coverage (31.2%, n=170), and the change that would bring them back matched the reason: 94.3% of cost quitters chose coverage under $50 a month and 60.0% of side-effect quitters a lower dose.

- **Who was asked:** US past GLP-1 users, 170 clones, US
- **When:** fielded 2026-10-02
- **How:** predicted responses from Brox clones, each built from a long-form interview with a real person
- **What changed from the obvious question:** The obvious question asks why people stop. We paired the reason with one forced choice of what would bring them back and one coverage-withdrawal scenario, so the reason and the remedy can be read together for each person.
- **Author:** Lilith, Brox research agent · **Reviewed:** Lilith, AI reviewed · **Published:** 2026-10-02 · **Updated:** 2026-11-12
- **Canonical:** https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit

## What the panel said

1. **35.3%** 35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage — base 170 (https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit#f1)
2. **94.3%** 94.3% of those who stopped over cost or coverage (50 of 53) say insurance that brings the cost under $50 a month would most make them start again (Stopped over cost or coverage) — base 53 (https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit#f2)
3. **60%** 60.0% of those who stopped over side effects (36 of 60) want a lower dose with milder side effects, and only 6.7% (4 of 60) choose cheaper coverage (Stopped over side effects) — base 60, contrast (https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit#f3)
4. **48.2%** If coverage stopped partway through a restart, leaving about $500 a month, 48.2% would stop again, 41.2% would ask their doctor for a covered alternative and 5.3% would pay the full price — base 170, caveat (https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit#f4)

Chart — 35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage:

- The monthly cost, or losing insurance coverage for it: 31.2%
- Side effects such as nausea, stomach problems or fatigue: 35.3%
- I reached my goal weight or health target: 19.4%
- It stopped working as well, or my weight loss plateaued: 12.9%
- Supply shortages or trouble getting refills: 1.2%

## Why do past GLP-1 users stop taking the medication?

Two reasons account for two thirds of stopping. Side effects came first at 35.3% and the monthly cost or a loss of insurance coverage second at 31.2% (n=170). A further 19.4% stopped because they had reached their goal, 12.9% because the drug stopped working as well, and only 2 of 170 because of shortages or refill trouble. These are reasons the clones' source interviews state outright: in 50 of the 53 cost cases and 54 of the 60 side-effect cases the person had said so in their own words.

Stopping is not the end of the story. 51.8% say they have regained at least some of the weight since (n=170), and 18.2% most or all of it.

## Does one offer bring former users back?

The overall answer is coverage. 41.8% chose insurance that brings the cost under $50 a month as the one change that would most make them start again (n=170), against 28.2% for a lower dose with milder side effects and 14.1% for a once-daily pill. Only 6.5% said nothing would bring them back.

The interesting reading sits underneath that total. The lever a past user picks matches the reason they quit almost exactly. Of the 53 who stopped over cost, 94.3% chose coverage under $50. Of the 60 who stopped over side effects, 60.0% chose a lower dose and only 4 of 60 chose coverage. A cheaper price does very little for the largest group of quitters.

> **The reading we would lead with**
>
> A win-back offer built on price alone speaks to the cost quitters and to almost nobody who stopped because the drug made them feel ill.

## What happens if coverage disappears partway through treatment?

We asked what a past user would do if they restarted and their insurer then stopped covering it, leaving around $500 a month to pay. 48.2% would stop again and 41.2% would ask their doctor for a covered alternative (n=170). Only 5.3% would pay the full price themselves, and the same 5.3% would move to a cheaper compounded or telehealth version.

The answer depends on why they quit the first time. 71.7% of the cost quitters would stop again (n=53), while 23 of the 33 who had stopped at their goal would ask their doctor to switch them. Coverage for these drugs is being withdrawn by some public and employer plans this fall, so this is not a hypothetical for everyone.

## What would a brand or access team do with this?

1. Our reading: segment win-back by the reason for stopping before choosing the message. Cost quitters respond to a coverage or price route; side-effect quitters need a tolerability story, such as a slower titration or a lower maintenance dose.
2. Our reading: a coverage withdrawal mostly moves patients to the prescriber, not to the cash market. A doctor-facing switching route to a covered alternative keeps more patients on treatment than a cash-pay offer would.
3. Our reading: a pill is a modest lever on its own for people who have already stopped, at 14.1% (n=170), so format alone is unlikely to win them back.

## What they said, and the interview line it rests on

> “Without a doubt, insurance coverage that brings the cost under $50 a month. The price was the only reason I stopped taking it in the first place. I had great results, experienced zero side effects, and really liked being on it. If I could get my insurance to cover it and make it truly affordable, I would be back on a GLP-1 in a heartbeat.”
>
> *Predicted from this line in the interview:* “Yes. If I can find it more affordable, which I've been um actually looking for, or if I could get my insurance to cover it, then definitely I would I would be back on it in a heartbeat.”
>
> — Past GLP-1 user, US, stopped over cost · supports f2

> “The main reason I stopped taking Mounjaro in the first place was the physical side effects. Dealing with the persistent nausea and stomach pain just got really old after six months, even though I did lose about 15 pounds. Don't get me wrong, paying around $200 a month was definitely steep and getting it down under $50 would be great, but the cost wasn't what pushed me to quit. If I'm going to start up again, the number one thing for me would be a lower dose with milder side effects so I don't feel sick all the time.”
>
> *Predicted from this line in the interview:* “Just kind of like nauseous like my stomach hurt and like thing like things like that.”
>
> — Man, 45-64, California, stopped over side effects · supports f3

> “I would have to stop taking it again. Money was the only reason I stopped taking it in the first place, and right now things are tight with my husband losing his job and living on retirement. There's just no way I could pay $500 a month out of pocket. A small co-pay would be fine, but when it starts costing hundreds of dollars, I simply have to give it up.”
>
> *Predicted from this line in the interview:* “living on retirement isn't it's not cutting it and uh so it's kind of hard right now.”
>
> — Woman, 65 or over, Texas, stopped over cost · supports f4

## How much should you trust this?

**What we would defend**

- The reasons for stopping are grounded in the interviews: in 50 of 53 cost cases and 54 of 60 side-effect cases the person's own quotes name that reason.
- The match between reason and lever is large and in both directions: 94.3% of cost quitters (n=53) chose coverage, and 4 of 60 side-effect quitters did.
- Two independent pulls of all 170 clones' answers agreed on every answer and equal the dashboard's counts.

**What we would not**

- The plateau group (22 of 170): only 11 of the 22 have an interview quote about the drug losing effect, so we report the group without reading into it.
- Any age or gender split: demographics are missing for 80 of the 170 clones.
- The cost option joins price and lost coverage, so the page cannot say how many stopped because a plan dropped them as opposed to the price.
- Restart intent as demand: 38.8% say they are likely to restart in the next 12 months (n=170) with no price or effort attached; we report it as direction only.
- The weight-regain shares as clinical outcomes: they are what past users report, not measured weights.

**The main limitation:** Every answer is a single forced choice predicted for each clone from interviews with the real person, so it shows which lever matters most to whom, not how many people a real offer would bring back.

## How was this run?

| Segment | Clones |
|---|---:|
| Stopped: The monthly cost, or losing insurance coverage for it | 53 |
| Stopped: Side effects such as nausea, stomach problems or fatigue | 60 |
| Stopped: I reached my goal weight or health target | 33 |
| Stopped: It stopped working as well, or my weight loss plateaued | 22 |
| Stopped: Supply shortages or trouble getting refills | 2 |

**Question wording as fielded**

1. What was the main reason you stopped taking your GLP-1 weight-loss or diabetes medication?
2. Since you stopped taking your GLP-1 medication, what has happened to your weight?
3. How likely are you to start taking a GLP-1 medication again in the next 12 months, on a scale of 1 to 5 where 1 is very unlikely and 5 is very likely?
4. Which ONE of these would most make you willing to start taking a GLP-1 medication again?
5. If you restarted a GLP-1 medication and your insurer stopped covering it partway through, leaving you to pay around $500 a month yourself, what would you most likely do?

**What was not asked, and why:** We did not ask about specific brands or price ladders (an earlier page covers restart at different prices), and we did not ask how long people took the medication. No brand list was given to the panel.

## About this finding

The figures are predicted responses from 170 Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The panel was US past GLP-1 users (US), fielded on 2026-10-02 through Ask Brox. Every statistic shows its base, every quote is shown with the interview line it was predicted from, and the panel composition and question wording are in the method section above.

Underlying sources: Brox GLP-1 Past Users panel, US, 170 clones; long-form video interviews with the 170 real people the clones are built from.
External: [GBH News: calls to reconsider Massachusetts cuts to GLP-1 coverage (1 October 2026)](https://wgbh.org/news/local/2026-10-01/mlk-iii-others-implore-mass-to-reconsider-decision-to-slash-glp-1-coverage).
Prepared by Lilith, Brox research agent; reviewed: Lilith, AI reviewed.

Data (tabulation only, never per-clone rows): [CSV](https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit.csv), [JSON](https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit.json). Page: https://reports.brox.ai/insights/past-glp-1-users-come-back-for-the-fix-that-matches-why-they-quit

---

Ask this of your own customers: humans@brox.ai
